scholarly journals Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primary biliary cholangitis patients

10.52586/5042 ◽  
2021 ◽  
Vol 26 (12) ◽  
pp. 1480-1492
Author(s):  
Naohiro Nakamura ◽  
Katsunori Yoshida ◽  
Rinako Tsuda ◽  
Miki Murata ◽  
Takashi Yamaguchi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Risk Assessment ◽  
Predictive Biomarker ◽  
Primary Biliary Cholangitis ◽  
Carcinoma Risk

scholarly journals Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging

2017 ◽  
Vol 49 (3) ◽  
pp. 302-310 ◽  
Author(s):  
Chiara Briani ◽  
Marco Di Pietropaolo ◽  
Massimo Marignani ◽  
Francesco Carbonetti ◽  
Paola Begini ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Risk Assessment ◽  
Diffusion Weighted Imaging ◽  
Gadoxetic Acid ◽  
Diffusion Weighted ◽  
Carcinoma Risk

Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis– the Global PBC Study Group

2018 ◽  
Vol 68 ◽  
pp. S229-S230
Author(s):  
W.J. Lammers ◽  
P. Trivedi ◽  
G. Hirschfield ◽  
C. Corpechot ◽  
A. Floreani ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Primary Biliary Cholangitis ◽  
Study Group ◽  
Carcinoma Risk

scholarly journals Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus

2021 ◽  
Author(s):  
Nobuharu Tamaki ◽  
Masayuki Kurosaki ◽  
Yutaka Yasui ◽  
Nami Mori ◽  
Keiji Tsuji ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Risk Assessment ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Advanced Fibrosis ◽  
Carcinoma Risk

Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging

2014 ◽  
Vol 44 (13) ◽  
pp. 1339-1346 ◽  
Author(s):  
Nobutoshi Komatsu ◽  
Utaroh Motosugi ◽  
Shinya Maekawa ◽  
Kuniaki Shindo ◽  
Minoru Sakamoto ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Hepatocellular Carcinoma ◽  
Risk Assessment ◽  
Magnetic Resonance ◽  
Gadoxetic Acid ◽  
Resonance Imaging ◽  
Carcinoma Risk

Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals

2018 ◽  
Vol 50 (6) ◽  
pp. 573-579 ◽  
Author(s):  
Federico Ravaioli ◽  
Fabio Conti ◽  
Stefano Brillanti ◽  
Pietro Andreone ◽  
Giuseppe Mazzella ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Risk Assessment ◽  
Liver Stiffness ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
Carcinoma Risk

scholarly journals Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1023
Author(s):  
Eirini I. Rigopoulou ◽  
George N. Dalekos
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Liver Diseases ◽  
Treatment Modalities ◽  
Primary Biliary Cholangitis ◽  
Autoimmune Liver Diseases ◽  
Increased Risk ◽  
Liver Cancers ◽  
Medium Risk ◽  
Causes Of Mortality

Hepatocellular carcinoma (HCC), the commonest among liver cancers, is one of the leading causes of mortality among malignancies worldwide. Several reports demonstrate autoimmune liver diseases (AILDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) to confer increased risk of hepatobiliary malignancies, albeit at lower frequencies compared to other liver diseases. Several parameters have been recognized as risk factors for HCC development in AIH and PBC, including demographics such as older age and male sex, clinical features, the most decisive being cirrhosis and other co-existing factors, such as alcohol consumption. Moreover, biochemical activity and treatment response have been increasingly recognized as prognostic factors for HCC development in AIH and PBC. As available treatment modalities are effective only when HCC diagnosis is established early, surveillance has been proven essential for HCC prognosis. Considering that the risk for HCC is not uniform between and within disease groups, refinement of screening strategies according to prevailing demographic, clinical, and molecular risk factors is mandated in AILDs patients, as personalized HCC risk prediction will offer significant advantage in patients at high and/or medium risk. Furthermore, future investigations should draw attention to whether modification of immunosuppression could benefit AIH patients after HCC diagnosis.

Sign in / Sign up

Export Citation Format

Share Document